$CRIS
CURIS INC Stock $cris

$cris Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000119312514300506 Filed on August 07, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$1.765M	$4.801M	$5.404M
YoY Change	-75.5%	-11.16%	24.19%
Cost Of Revenue	$90.00K	$90.00K	$40.00K
YoY Change	80.0%	125.0%	300.0%
Gross Profit	$1.680M	$4.710M	$5.360M
YoY Change	-76.5%	-12.13%	23.5%
Gross Profit Margin	95.19%	98.1%	99.18%
Selling, General & Admin	$2.720M	$2.930M	$2.900M
YoY Change	-4.56%	1.03%	28.32%
% of Gross Profit	161.9%	62.21%	54.1%
Research & Development	$3.705M	$3.329M	$3.167M
YoY Change	-11.16%	5.13%	-29.64%
% of Gross Profit	220.56%	70.68%	59.08%
Depreciation & Amortization	$40.00K	$30.00K	$40.00K
YoY Change	33.33%	-25.0%	33.33%
% of Gross Profit	2.38%	0.64%	0.75%
Operating Expenses	$3.705M	$3.329M	$3.167M
YoY Change	-11.16%	5.13%	-29.64%
Operating Profit	-$4.753M	-$1.545M	-$706.2K
YoY Change	-3745.86%	118.75%	-70.89%
Interest Expense	$933.9K	$949.7K	$957.7K
YoY Change	-3.18%	-0.84%	-308.2%
% of Operating Profit
Other Income/Expense, Net	-$827.1K	-$351.0K	-$587.7K
YoY Change	-58.61%	-40.27%	27.65%
Pretax Income	-$5.580M	-$1.900M	-$1.290M
YoY Change	198.4%	47.29%	-55.36%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.580M	-$1.896M	-$1.294M
YoY Change	198.75%	46.52%	-55.18%
Net Earnings / Revenue	-316.18%	-39.48%	-23.94%
Basic Earnings Per Share
Diluted Earnings Per Share	-$324.4K	-$110.5K	-$79.48K
COMMON SHARES
Basic Shares Outstanding	86.00M shares	85.95M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$54.60M	$55.80M	$57.10M
YoY Change	-13.61%	-2.28%	27.74%
Cash & Equivalents	$7.933M	$10.16M	$9.743M
Short-Term Investments	$46.70M	$45.60M	$47.40M
Other Short-Term Assets	$700.0K	$400.0K	$400.0K
YoY Change	40.0%	0.0%	0.0%
Inventory
Prepaid Expenses
Receivables	$1.839M	$4.843M	$863.2K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$57.11M	$60.99M	$58.42M
YoY Change	-12.0%	4.39%	28.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$407.4K	$439.4K	$500.9K
YoY Change	-12.86%	-12.28%	25.22%
Goodwill	$8.982M	$8.982M	$8.982M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$1.500M	$3.300M	$0.00
YoY Change	-61.54%
Other Assets	$77.56K	$78.31K	$129.8K
YoY Change	-33.66%	-39.66%	-35.11%
Total Long-Term Assets	$11.10M	$12.91M	$9.779M
YoY Change	-18.7%	32.01%	1.87%
TOTAL ASSETS
Total Short-Term Assets	$57.11M	$60.99M	$58.42M
Total Long-Term Assets	$11.10M	$12.91M	$9.779M
Total Assets	$68.21M	$73.90M	$68.20M
YoY Change	-13.16%	8.35%	24.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.371M	$2.849M	$2.578M
YoY Change	3.52%	10.51%	7.43%
Accrued Expenses	$1.942M	$1.510M	$1.419M
YoY Change	-1.77%	6.37%	29.02%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.522M	$5.499M	$1.368M
YoY Change	280.81%	302.06%
Total Short-Term Liabilities	$9.835M	$9.925M	$5.365M
YoY Change	72.01%	85.0%	53.29%
LONG-TERM LIABILITIES
Long-Term Debt	$23.54M	$24.37M	$29.03M
YoY Change	-19.19%	-16.04%
Other Long-Term Liabilities	$187.4K	$191.1K	$199.1K
YoY Change	-5.3%	-4.03%	-95.58%
Total Long-Term Liabilities	$23.73M	$24.56M	$29.23M
YoY Change	-19.1%	-15.96%	549.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.835M	$9.925M	$5.365M
Total Long-Term Liabilities	$23.73M	$24.56M	$29.23M
Total Liabilities	$33.56M	$34.49M	$35.45M
YoY Change	-9.23%	-2.7%	343.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$773.9M	-$768.3M	-$754.8M
YoY Change	2.28%	1.79%
Common Stock	$872.3K	$872.3K	$829.1K
YoY Change	2.2%	5.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.524M	$1.524M	$1.524M
YoY Change	0.0%	0.0%
Treasury Stock Shares	1.223M shares	1.223M shares	1.223M shares
Shareholders Equity	$34.65M	$39.41M	$32.76M
YoY Change
Total Liabilities & Shareholders Equity	$68.21M	$73.90M	$68.20M
YoY Change	-13.16%	8.35%	24.01%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$5.580M	-$1.896M	-$1.294M
YoY Change	198.75%	46.52%	-55.18%
Depreciation, Depletion And Amortization	$40.00K	$30.00K	$40.00K
YoY Change	33.33%	-25.0%	33.33%
Cash From Operating Activities	-$2.080M	-$4.730M	$30.00K
YoY Change	-870.37%	-15866.67%	-102.42%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$60.00K	$0.00
YoY Change	-90.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$690.0K	$6.960M	-$2.890M
YoY Change	-111.58%	-340.83%	29.6%
Cash From Investing Activities	$680.0K	$6.900M	-$2.890M
YoY Change	-111.22%	-338.75%	27.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-820.0K	80.00K	2.890M
YoY Change	-108.35%	-97.23%	224.72%
NET CHANGE
Cash From Operating Activities	-2.080M	-4.730M	30.00K
Cash From Investing Activities	680.0K	6.900M	-2.890M
Cash From Financing Activities	-820.0K	80.00K	2.890M
Net Change In Cash	-2.220M	2.250M	30.00K
YoY Change	-155.09%	7400.0%	-101.15%
FREE CASH FLOW
Cash From Operating Activities	-$2.080M	-$4.730M	$30.00K
Capital Expenditures	-$10.00K	-$60.00K	$0.00
Free Cash Flow	-$2.070M	-$4.670M	$30.00K
YoY Change	-659.46%	-15666.67%	-102.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	86004857	shares
CY2013Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	853778
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9742938
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86004857	shares
CY2014Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1373517	shares
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7401
CY2014Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	191076
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	39412357
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87227703	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2014Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	3.55
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1509632
CY2014Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	24450416
CY2014Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	24372065
CY2014Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	811916
CY2014Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	166116
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	808342990
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2849252
CY2014Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	219450
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9925464
CY2014Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	67910
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-768286282
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	872277
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73900962
CY2014Q2	us-gaap	Liabilities Liabilities	34488605
CY2014Q2	us-gaap	Interest Payable Current InterestPayableCurrent	312150
CY2014Q2	us-gaap	Liabilities Fair Value Disclosure Nonrecurring LiabilitiesFairValueDisclosureNonrecurring	0
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	5498670
CY2014Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	45614450
CY2014Q2	us-gaap	Long Term Investments LongTermInvestments	3257209
CY2014Q2	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	13877
CY2014Q2	us-gaap	Assets Current AssetsCurrent	60991474
CY2014Q2	us-gaap	Goodwill Goodwill	8982000
CY2014Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	44604196
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	78312
CY2014Q2	us-gaap	Assets Assets	73900962
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10156360
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4843412
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1837000
CY2014Q2	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	126797
CY2014Q2	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	152610
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	363375
CY2014Q2	cris	Debt Instrument Current Carrying Amount DebtInstrumentCurrentCarryingAmount	5552199
CY2014Q2	cris	Warrant Liability Current WarrantLiabilityCurrent	67910
CY2014Q2	cris	Stock Issued During Period Due To Exercise Of Warrants StockIssuedDuringPeriodDueToExerciseOfWarrants	238805	shares
CY2014Q2	cris	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	7153
CY2014Q2	cris	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	14547
CY2010Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1612322	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1906000
CY2014Q2	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	1002861
CY2014Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6192000
CY2014Q2	us-gaap	Assets Fair Value Disclosure Nonrecurring AssetsFairValueDisclosureNonrecurring	0
CY2014Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	44611590
CY2014Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1524029
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	439357
CY2010Q1	cris	Registered Direct Offering Number Of Common Stock Per Unit RegisteredDirectOfferingNumberOfCommonStockPerUnit	1
CY2010Q1	cris	Registered Direct Offering Units RegisteredDirectOfferingUnits	6449288	shares
CY2010Q1	cris	Registered Direct Offering Number Of Warrant Per Unit RegisteredDirectOfferingNumberOfWarrantPerUnit	1
CY2010Q1	cris	Direct Offering Purchase Price DirectOfferingPurchasePrice	2.52
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1488179
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12747709
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	85859016	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87081862	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1911479
CY2013Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	28050291
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	27945186
CY2013Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1267954
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	178390
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	806660340
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2036864
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	166200
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6558517
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6984
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	196734
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	45173585
CY2013Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	716786
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-760826561
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	870819
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	80590808
CY2013Q4	us-gaap	Liabilities Liabilities	35417223
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	298935
CY2013Q4	us-gaap	Liabilities Fair Value Disclosure Nonrecurring LiabilitiesFairValueDisclosureNonrecurring	0
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2610174
CY2013Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	48588135
CY2013Q4	us-gaap	Long Term Investments LongTermInvestments	10726685
CY2013Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	13877
CY2013Q4	us-gaap	Assets Current AssetsCurrent	60165947
CY2013Q4	us-gaap	Goodwill Goodwill	8982000
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	47592763
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	104034
CY2013Q4	us-gaap	Assets Assets	80590808
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9591487
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1477188
CY2013Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	152496
CY2013Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	166487
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	495260
CY2013Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	1001802
CY2013Q4	us-gaap	Assets Fair Value Disclosure Nonrecurring AssetsFairValueDisclosureNonrecurring	0
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	47586333
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1524029
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	445655
CY2013Q4	cris	Debt Instrument Current Carrying Amount DebtInstrumentCurrentCarryingAmount	2663677
CY2013Q4	cris	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	716786
CY2013Q4	cris	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	15476
CY2013Q4	cris	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	9046
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.70	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	640000	shares
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.20
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.65	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	400000	shares
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.34
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	80615412	shares
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4304249
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.14
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12036836	shares
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-44877
	us-gaap	Revenues Revenues	6275812
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	34941
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6262382
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1808000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	27704396
	us-gaap	Licenses Revenue LicensesRevenue	4000000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	261475
	us-gaap	Investment Income Interest InvestmentIncomeInterest	78561
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5063560
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	634401
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1192582
	us-gaap	Net Income Loss NetIncomeLoss	-6256142
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-163826
	us-gaap	Royalty Revenue RoyaltyRevenue	1469712
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34957
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-13918
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	133810
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-634401
	us-gaap	Costs And Expenses CostsAndExpenses	11339372
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5470791
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2927878
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1598000
	us-gaap	Share Based Compensation ShareBasedCompensation	1576537
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	67734
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1951893
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3004771
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1628400
	us-gaap	Interest Expense InterestExpense	1905544
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3189353
	us-gaap	Royalty Expense RoyaltyExpense	73485
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5795096
	us-gaap	Interest Costs Incurred Capitalized InterestCostsIncurredCapitalized	582062
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	52389
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	26097035
	cris	Research And Development Revenue ResearchAndDevelopmentRevenue	806100
	cris	Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees	180510
	dei	Trading Symbol TradingSymbol	CRIS
	dei	Entity Registrant Name EntityRegistrantName	CURIS INC
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001108205
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">  </p> <!-- xbrl,n --> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="3%" align="left"><b>1.</b></td> <td style="FONT-SIZE: 8pt" valign="top" width="1%"> </td> <td valign="top" align="left"><b><u>Nature of Business</u></b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Curis, Inc. is an oncology-focused company seeking to develop novel drug candidates for the treatment of human cancers. As used throughout these consolidated financial statements, the term “the Company” refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term “Curis” refers to Curis, Inc.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company conducts its research and development programs both internally and through strategic collaborations. The Company is leveraging its experience in targeting signaling pathways in seeking to develop drug candidates including CUDC-907, a dual histone deacetylase, or HDAC and phosphoinositide-3 kinase, or PI3K, inhibitor, and CUDC-427, a small molecule antagonist of the inhibitor of apoptosis, or IAP, proteins. Erivedge<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup>, the first and only approved medicine for the treatment of advanced basal cell carcinoma, or BCC, is being commercialized by F. Hoffmann-La Roche Ltd., or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. The Company’s licensee Debiopharm is conducting the clinical development of the heat shock protein 90, or HSP90, inhibitor, Debio 0932.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United States by the Food and Drug Administration, or FDA, and in overseas markets by similar regulatory authorities.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company is subject to risks common to companies in the biotechnology industry as well as risk factors that are specific to the Company’s business, including, but not limited to: the Company’s reliance on Genentech and Roche to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress it’s clinical development in indications other than BCC; the Company’s ability to advance and expand its research and development programs; the Company’s ability to obtain adequate financing to fund its operations; the ability of the Company’s wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its loan agreement with BioPharma Secured Debt Fund II Sub, S.à r.l., a Luxembourg limited liability company managed by Pharmakon Advisors, or BioPharma-II; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; dependence on key personnel; the Company’s ability to comply with regulatory requirements; and the Company’s ability to execute on its overall business strategies.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company’s future operating results will largely depend on the magnitude of payments from its current and potential future corporate collaborators and the progress of drug candidates currently in its development pipeline. The results of the Company’s operations will vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: Roche and Genentech’s ability to successfully commercialize Erivedge; positive results in Genentech’s ongoing clinical trials; the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates; and the Company’s ability to successfully enter into one or more material licenses or collaboration agreements for its proprietary drug candidates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company anticipates that existing cash, cash equivalents and investments at June 30, 2014 should enable it to maintain current and planned operations into 2016. The Company’s ability to continue funding its planned operations beyond this period is dependent upon, among other things, the success of its collaborations with Genentech, Debiopharm and the Leukemia & Lymphoma Society, or LLS, including its receipt of additional contingent cash payments under these collaborations; its ability to control expenses and its ability to raise additional funds through equity or debt financings, new collaborations or other sources of financing. The Company may not be able to successfully raise additional funds or enter into or continue any corporate collaborations and the timing, amount and likelihood of the Company receiving payments under such collaborations is highly uncertain. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay spending on its research and/or development programs.</p> </div>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	400000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P60D
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85940842	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.75
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10035486
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.82
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12763386	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	Segment
	us-gaap	Revenues Revenues	6085918
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-131908
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7445336
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1376000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	25347887
	us-gaap	Repayments Of Debt RepaymentsOfDebt	2546417
	us-gaap	Licenses Revenue LicensesRevenue	3000000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	90239
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6298130
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	648876
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3366224
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1161591
	us-gaap	Net Income Loss NetIncomeLoss	-7459721
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-69046
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	1835064
	us-gaap	Royalty Revenue RoyaltyRevenue	3112183
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	58861
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-13877
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	395205
	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	711353
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-648876
	us-gaap	Costs And Expenses CostsAndExpenses	12384048
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5752157
	us-gaap	Paid In Kind Interest PaidInKindInterest	-711353
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	256843
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	105000
	us-gaap	Share Based Compensation ShareBasedCompensation	1427265
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	74837
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-2575765
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	564873
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	10343516
	us-gaap	Interest Expense InterestExpense	1900706
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	256843
	us-gaap	Royalty Expense RoyaltyExpense	156985
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6474906
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	52427
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	156377
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	35736387
	cris	Share Based Compensation Plans ShareBasedCompensationPlans	2	Plans
	cris	Available For Sale Securities Weighted Average Maturity AvailableForSaleSecuritiesWeightedAverageMaturity	P6M
	cris	Debt Issuance Costs Gross DebtIssuanceCostsGross	421715
	cris	Share Based Compensation Arrangement By Share Based Payment Award Options Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssued	1040000	shares
	cris	Research And Development Revenue ResearchAndDevelopmentRevenue	-26265
	cris	Class Of Warrant Or Right Expiration Year And Month ClassOfWarrantOrRightExpirationYearAndMonth	2015-01
	cris	Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees	54762
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	640000	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.09
CY2010Q1	cris	Proceeds From Registered Direct Offering Of Common Stock And Warrants Net Of Issuance Costs ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts	14942000
CY2013	cris	Available For Sale Securities Weighted Average Maturity AvailableForSaleSecuritiesWeightedAverageMaturity	P4M21D
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81128475	shares
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12036836	shares
CY2013Q2	us-gaap	Revenues Revenues	5404377
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1299031
CY2013Q2	us-gaap	Licenses Revenue LicensesRevenue	4000000
CY2013Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	36949
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-706196
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-587652
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-1293848
CY2013Q2	us-gaap	Royalty Revenue RoyaltyRevenue	805312
CY2013Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-333141
CY2013Q2	us-gaap	Costs And Expenses CostsAndExpenses	6110573
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2903669
CY2013Q2	us-gaap	Share Based Compensation ShareBasedCompensation	915971
CY2013Q2	us-gaap	Interest Expense InterestExpense	957742
CY2013Q2	us-gaap	Royalty Expense RoyaltyExpense	40265
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3166639
CY2013Q2	cris	Research And Development Revenue ResearchAndDevelopmentRevenue	599065
CY2013Q2	cris	Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees	164269
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85963836	shares
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12763386	shares
CY2014Q2	us-gaap	Revenues Revenues	4801285
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1885634
CY2014Q2	us-gaap	Licenses Revenue LicensesRevenue	3000000
CY2014Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	41479
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1544787
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-350998
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-1895785
CY2014Q2	us-gaap	Royalty Revenue RoyaltyRevenue	1823935
CY2014Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-557253
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	6346072
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2925259
CY2014Q2	us-gaap	Share Based Compensation ShareBasedCompensation	683821
CY2014Q2	us-gaap	Interest Expense InterestExpense	949730
CY2014Q2	us-gaap	Royalty Expense RoyaltyExpense	91837
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3328976
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	108366
CY2014Q2	cris	Research And Development Revenue ResearchAndDevelopmentRevenue	-22650
CY2014Q2	cris	Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees	110434

Files In Submission

Name	View Source	Status
0001193125-14-300506-index-headers.html	Edgar Link	pending
0001193125-14-300506-index.html	Edgar Link	pending
0001193125-14-300506.txt	Edgar Link	pending
0001193125-14-300506-xbrl.zip	Edgar Link	pending
cris-20140630.xml	Edgar Link	completed
cris-20140630.xsd	Edgar Link	pending
cris-20140630_cal.xml	Edgar Link	unprocessable
cris-20140630_def.xml	Edgar Link	unprocessable
cris-20140630_lab.xml	Edgar Link	unprocessable
cris-20140630_pre.xml	Edgar Link	unprocessable
d743353d10q.htm	Edgar Link	pending
d743353dex101.htm	Edgar Link	pending
d743353dex102.htm	Edgar Link	pending
d743353dex103.htm	Edgar Link	pending
d743353dex311.htm	Edgar Link	pending
d743353dex312.htm	Edgar Link	pending
d743353dex321.htm	Edgar Link	pending
d743353dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRIS
CURIS INC Stock $cris

2014 Q3 Form 10-Q Financial Statement

#000119312514300506 Filed on August 07, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS CURIS INC Stock $cris

2014 Q3 Form 10-Q Financial Statement

#000119312514300506 Filed on August 07, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS
CURIS INC Stock $cris